Status:
RECRUITING
Efficacy of Clopidogrel on Incidence of Silent Brain Infarction
Lead Sponsor:
VA Office of Research and Development
Conditions:
Silent Brain Infarction
Eligibility:
All Genders
21-90 years
Phase:
PHASE4
Brief Summary
Silent brain infarctions (SBIs) are a manifestation of covert cerebrovascular disease, without obvious clinical deficit, noted very often in patients presenting with a new stroke or new transient isch...
Detailed Description
Introduction: Silent brain infarcts (SBIs) are a recently recognized, commonly noted and yet poorly understood finding of cerebral infarction on imaging studies without a clinically apparent neurolog...
Eligibility Criteria
Inclusion
- diagnosis of ischemic stroke/TIA
- \< 90 days from onset of symptoms
- initial MRI available,
- not receiving antiplatelet therapy at the time of admission
- medical decision by the treating physician that antiplatelet therapy is indicated for secondary prevention (decision independent of the study and based on individual clinical decision for each patient).
- baseline coated-platelet levels at 40%,
- willingness to participate in the study for 24 months
Exclusion
- dementia (based on chart review or self/proxy report)
- \> 90 days from onset of symptoms
- initiation of anticoagulation or thrombolytics prior to phlebotomy
- intracranial hemorrhage or bleeding diatheses
- end-stage renal disease (ESRD)
- inability to tolerate consenting or phlebotomy
- prior adverse/allergic reactions to clopidogrel
- treating physician deemed a different antiplatelet dose or dual antiplatelet therapy as the only treatment choice
Key Trial Info
Start Date :
March 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2026
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT04698031
Start Date
March 30 2022
End Date
May 30 2026
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oklahoma City VA Medical Center, Oklahoma City, OK
Oklahoma City, Oklahoma, United States, 73104-5007